huntersyndromeupdates.com Open in urlscan Pro
192.185.170.235  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Menu
 * 
 * Our 094 Study
 * MPS II Drug Development
 * Hear From MPS II Experts


Menu
 * 
 * Our 094 Study
 * MPS II Drug Development
 * Hear From MPS II Experts





THE UNMET MEDICAL NEEDS OF THE RARE DISEASE COMMUNITY HAVE DRIVEN OUR PURSUIT OF
NEW THERAPIES ON BEHALF OF PATIENTS FOR OVER 20 YEARS.  



THE UNMET MEDICAL NEEDS OF THE RARE DISEASE COMMUNITY HAVE DRIVEN OUR PURSUIT OF
NEW THERAPIES ON BEHALF OF PATIENTS FOR OVER 20 YEARS.  


We invite you to explore this website to learn more about Takeda's clinical
development program for patients with Hunter syndrome and cognitive impairment. 




Click Here to Read About the History of Hunter Syndrome

and Our Long-Standing Commitment to the Hunter Community. 






OUR 094 STUDY


READ THE
PRELIMINARY RESULTS





  Our official press release shares the top-line data results from the
HGT-HIT-094 clinical trial evaluating TAK-609 for pediatric patients with Hunter
syndrome and cognitive impairment.




LEARN ABOUT
THE 094 STUDY 





Visit the U.S. and E.U. regulatory websites
for more details about our 094 program,
and check for updates to the
sites in the future.
 


CHALLENGES IN RARE DISEASE CLINICAL TRIALS
 





   David A.H. Whiteman, M.D.
Vice President Research and Development    
 Discusses the company's historic work with the Hunter syndrome community and
the challenges of designing a trial for rare disease like MPS II.





MPS II DRUG DEVELOPMENT 


PATHWAY TO
DRUG APPROVAL
 





What does it take to get a rare disease treatment approved by regulatory
authorities? Learn what the pathway to approval looks like in this animated
video.



DEVELOPING
NEW MEDICINES
  





Why is developing new medicines so challenging? Why are clinical study endpoints
and natural history studies so important? Learn more about the R&D process for
rare diseases.




HEAR FROM MPS II EXPERTS 


HEAR FROM THE TRIAL
PRINCIPAL INVESTIGATOR (PI)






Joseph Muenzer, M.D., Ph.D.
Professor, Pediatric Genetics and Metabolism Genetics,
UNC Chapel Hill School of Medicine
Describes his first-hand experiences working with MPS II patients and families
and conducting trials for rare diseases with cognitive impairment.

Prof. Muenzer is a paid consultant for Takeda.






DRUG DEVELOPMENT
FOR RARE DISEASE



POTENTIAL ACCESS TO MEDICINES  


What is Shire’s Continuum of Access to Medicines model and how does it work to
improve access to medicines?
Learn more about Shire’s non-commercial route to medicines.  



To learn more about Hunter syndrome, please visit: 

In the U.S. 
www.hunterpatients.com  
Outside the U.S.
www.huntersyndrome.info  

















All content of this website including text, images, graphics, sound files, and
their arrangement, belongs to Takeda and is protected by international copyright
laws. All other intellectual property rights are reserved. The content may not
be copied for commercial use or distribution, nor may these objects be
downloaded, modified, or posted to other sites. This site is intended for both
international and U.S. audiences and is governed by U.S. and international laws
and government regulations. Please see our  Terms of Use and online Privacy
Notice for more information. While Takeda makes reasonable efforts to include
accurate, up-to-date information on the site, Takeda makes no warranties or
representations as to its accuracy. Takeda assumes no liability for any errors
or omissions in the content of the site.


US-SHP-0016v2.0 02/22


 © 2022 Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421. 1-877-TAKEDA-7
(877-825-3327). All rights reserved.
TAKEDA and the TAKEDA logo are registered trademarks of Takeda Pharmaceutical
Company Limited.




By following this link you will be leaving www.HunterSyndromeUpdates.com. Takeda
has no influence or control over the content of third-party websites.

Select your location:

 





By following this link you will be leaving www.HunterSyndromeUpdates.com. Takeda
has no influence or control over the content of third-party websites.
Please note that this content is intended for audiences outside the United
States only.





By following this link you will be leaving www.HunterSyndromeUpdates.com. Takeda
has no influence or control over the content of third-party websites.





By following this link you will be leaving www.HunterSyndromeUpdates.com. Takeda
has no influence or control over the content of third-party websites.





By following this link you will be leaving www.HunterSyndromeUpdates.com for
another Takeda website. Please note that this content is intended for audiences
inside the United States only.





By following this link you will be leaving www.HunterSyndromeUpdates.com for
another Takeda website. Please note that this content is intended for audiences
outside the United States only.





Your browser does not support HTML5 video.

David
00:00
--
/
--


Your browser does not support HTML5 video.

Howard
00:00
--
/
--